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ABSTRACT
Introduction Diabetic neuropathy can be diagnosed and 
assessed using a number of techniques including corneal 
confocal microscopy (CCM).
Research design and methods We have undertaken 
quantitative sensory testing, nerve conduction studies 
and CCM in 143 patients with type 1 and type 2 diabetes 
without neuropathy (n=51), mild neuropathy (n=47) and 
moderate to severe neuropathy (n=45) and age- matched 
controls (n=30).
Results Vibration perception threshold (p<0.0001), 
warm perception threshold (WPT) (p<0.001), sural nerve 
conduction velocity (SNCV) (p<0.001), corneal nerve fiber 
density (CNFD) (p<0.0001), corneal nerve branch density 
(CNBD) (p<0.0001), corneal nerve fiber length (CNFL) 
(p=0.002), inferior whorl length (IWL) (p=0.0001) and 
average nerve fiber length (ANFL) (p=0.0001) showed 
a progressive abnormality with increasing severity of 
diabetic neuropathy. Receiver operating characteristic 
curve analysis for the diagnosis of diabetic neuropathy 
showed comparable performance in relation to the 
area under the curve (AUC) but differing sensitivities 
and specificities for vibration perception threshold 
(AUC 0.79, sensitivity 55%, specificity 90%), WPT (AUC 
0.67, sensitivity 50%, specificity 76%), cold perception 
threshold (AUC 0.64, sensitivity 80%, specificity 47%), 
SNCV (AUC 0.70, sensitivity 76%, specificity 54%), CNFD 
(AUC 0.71, sensitivity 58%, specificity 83%), CNBD (AUC 
0.70, sensitivity 69%, specificity 65%), CNFL (AUC 0.68, 
sensitivity 64%, specificity 67%), IWL (AUC 0.72, sensitivity 
70%, specificity 65%) and ANFL (AUC 0.72, sensitivity 
71%, specificity 66%).
Conclusion This study shows that CCM identifies early 
and progressive corneal nerve loss at the inferior whorl 
and central cornea and has comparable utility with 
quantitative sensory testing and nerve conduction in the 
diagnosis of diabetic neuropathy.
INTRODUCTION
Corneal confocal microscopy (CCM) has been 
used to identify nerve fiber degeneration in 
patients with diabetic neuropathy.1–5 It is a 
rapid, non- invasive nerve imaging technique 
with high reproducibility and moderate to 
high sensitivity and specificity in the diagnosis 
of diabetic peripheral neuropathy (DPN).3 6–10 
To date, most studies have undertaken central 
corneal nerve assessment. However, recent 
animal and small human studies suggest that 
quantification of corneal nerve morphology 
at the inferior whorl may detect earlier nerve 
fiber damage.11–14 Given that DPN is a length- 
dependent distal axonopathy, nerves at the 
inferior whorl are expected to be affected 
before central corneal nerves.15 Indeed, we 
have previously shown greater corneal nerve 
loss at the inferior whorl compared with the 
Significance of this study
What is already known about this subject?
 ► Corneal nerve loss may allow the diagnosis of dia-
betic neuropathy.
What are the new findings?
 ► There is progressive loss of corneal nerves at the 
central and inferior whorl region with increasing se-
verity of diabetic neuropathy.
 ► Inferior whorl length was reduced while central cor-
neal nerve fiber length was still preserved in patients 
without diabetic neuropathy, consistent with an early 
distal axonopathy.
 ► Corneal confocal microscopy has comparable utility 
with quantitative sensory testing and nerve conduc-
tion studies in the diagnosis of diabetic neuropathy.
How might these results change the focus of 
research or clinical practice?
 ► Corneal confocal microscopy may be used to diag-
nose and stratify the severity of diabetic neuropathy.
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central cornea,13 14 16 even though central corneal nerve 
fiber length (CNFL) is considered to be optimal for 
diagnosing DPN.17–19 While Pritchard et al13 reported 
a comparable diagnostic utility for central and inferior 
whorl corneal nerve length, Petropoulos et al14 showed 
that inferior whorl length (IWL) increased the sensi-
tivity in diagnosing DPN. More recently, Kalteniece et al16 
combined CNFL and IWL and showed that it was more 
reliable than either alone, in identifying patients with 
diabetic neuropathy. Corneal nerve loss in larger images 
incorporating nerves from the center and inferior whorl 
has been demonstrated in patients with recently diag-
nosed type 2 diabetes.20 Furthermore, in our recent 
longitudinal study, a reduction in IWL occurred more 
rapidly than CNFL in patients with diabetic neuropathy.21
We have compared the utility of quantifying corneal 
nerve loss at the inferior whorl and central cornea with 
quantitative sensory testing and nerve conduction in the 
diagnosis and assessment of the severity of DPN.
RESEARCH DESIGN AND METHODS
Study participants
One hundred and forty- three patients with diabetes and 
30 control participants underwent a comprehensive 
assessment of peripheral neuropathy and CCM. Each 
participant provided informed consent prior to partici-
pation in the study.
Patients were excluded if they had a history of connec-
tive tissue or infectious disease, malignancy, deficiency in 
B12 or folate, chronic renal and liver failure, current or 
active diabetic foot ulceration, previous ocular trauma, 
systemic disease other than diabetes that could cause 
neuropathy or affect the cornea, corneal surgery, and a 
history of or current contact lens wear.
Clinical and peripheral neuropathy assessment
Each participant underwent assessment of body mass 
index (BMI), blood pressure, glycated hemoglobin 
(HbA1c) and lipid profile. The simplified Neuropathy 
Disability Score (NDS), which assesses vibration, pinprick, 
temperature perception, and presence or absence of 
ankle reflexes, was used to stratify patients into three 
groups: no (NDS=0–2), mild (NDS=3–5) and moderate 
to severe (NDS=6–10) neuropathy.22
Vibration perception threshold (VPT) was assessed 
using a neurothesiometer (Scientific Laboratory 
Supplies, Wilford, Nottingham, UK), and cold percep-
tion threshold (CPT) and warm perception threshold 
(WPT) were tested on the dorsolateral aspect of the non- 
dominant foot (S1) using a TSA- II NeuroSensory Analyzer 
(Medoc, Ramat Yishai, Israel). Electrodiagnostic studies 
were undertaken by a consultant neurophysiologist using 
a Dantec ‘Keypoint’ system (Dantec Dynamics, Bristol, 
UK) equipped with a thermistor (DISA temperature 
regulator, Denmark) to keep the limb temperature at 
32°C–35°C and sural nerve conduction velocity (SNCV) 
was tested.
Ophthalmic assessment
Examinations of the anterior ocular segment using 
slit- lamp biomicroscopy and CCM examination using 
laser scanning CCM (Heidelberg Retina Tomograph 
III Rostock Cornea Module; Heidelberg Engineering, 
Heidelberg, Germany) were performed for both eyes 
according to our established protocol.23
Six images (three per eye) from the central sub- basal 
nerve plexus and four images (two per eye) from the 
inferior whorl region were selected and manually quan-
tified using CCMetrics (The University of Manchester, 
Manchester, UK). Images were selected by a single expert 
in a masked fashion taking into account the quality, 
depth and variability following our previously estab-
lished protocol.3 14 Corneal nerve fiber density (CNFD; 
total number of main nerves per square millimeter) 
(no./mm2), corneal nerve branch density (CNBD; total 
number of branches per square millimeter) (no./mm2), 
CNFL (total length of main nerves and nerve branches 
per square millimeter) (mm/mm2), IWL (total length of 
nerves per square millimeter) (mm/mm2) and average 
nerve fiber length (ANFL=CNFL+IWL/2) (mm/mm2) 
were quantified.17
Statistical analysis
Analysis was carried out using SPSS V.22.0 for Windows. 
The Shapiro- Wilk test was employed to assess whether 
data were normally distributed. Fisher’s exact test was 
used to test the association between two categorical vari-
ables. Analysis of variance and analysis of covariance 
with least significant difference correction were used 
for multiple comparisons between groups. All data were 
expressed as mean±SEM. P<0.05 was considered signifi-
cant. Graphs were created using GraphPad Prism (V.7.0c 
for Windows; GraphPad Software, La Jolla, California, 
USA). Receiver operating characteristic (ROC) curves 
were used to define the optimum cut- off points with 
the highest sensitivity and specificity in the diagnosis of 
DPN, and Youden’s index (J=sensitivity+specificity−1) was 
measured.
RESULTS
Clinical, demographic and laboratory findings
All participant groups were matched for gender (p=0.4) 
and ethnicity (p=0.3). Age (p=0.003), duration of diabetes 
(p=0.01), HbA1c (p<0.0001), BMI (p=0.04) and low- 
density lipoprotein cholesterol (p<0.0001) were signifi-
cantly different between all participant groups. There 
was no difference in high- density lipoprotein cholesterol 
(p=0.4) or triglycerides (p=0.7) between groups (table 1).
Peripheral neuropathy assessment
VPT was significantly higher in patients with no 
(12.2±1.24, p=0.02), mild (15.05±1.2, p<0.0001) and 
moderate to severe (25.56±1.35, p<0.0001) neuropathy 
compared with controls (7.1±1.80) (table 2). CPT was 
significantly lower only in patients with mild (19.52±1.47, 
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p=0.02) and moderate to severe (18.99±1.55, p=0.01) 
neuropathy compared with controls (25.38±2.06). WPT 
was significantly higher in patients with no (41.65±0.6, 
p=0.01), mild (43.47±0.6, p<0.0001) and moderate to 
severe (43.62±0.7, p<0.0001) neuropathy compared with 
controls (38.87±0.9). SNCV was significantly lower in 
patients with no (43.14±1.56, p=0.001), mild (43.5±1.69, 
p=0.002) and moderate to severe (40.19±1.79, p<0.0001) 
neuropathy compared with controls (52.09±2.1).
Corneal confocal microscopy
CNFD was significantly lower in patients with no 
(26.61±1.05, p<0.0001), mild (24.47±1.09, p<0.0001) and 
moderate to severe (22.4±1.14, p<0.0001) neuropathy 
compared with controls (33.71±1.3) (figure 1, table 2). 
CNBD was significantly lower in patients with no 
(64.07±4.39, p=0.01), mild (58.49±4.76, p=0.002) and 
moderate to severe (45.60±4.50, p<0.0001) neurop-
athy compared with controls (81.52±5.54). CNFL was 
significantly lower in patients with mild (20.84±1.004, 
p=0.01) and moderate to severe (19.27±1.04, p=0.001) 
neuropathy compared with controls (25.07±1.27). IWL 
was significantly lower in patients with no (24.9±1.26, 
p=0.001), mild (22.28±1.31, p<0.0001) and moderate to 
severe (19.03±1.36, p<0.0001) neuropathy compared with 
controls (31.69±1.66). ANFL was significantly lower in 
patients with no (24.1±0.98, p=0.009), mild (21.56±1.02, 
Table 1 Demographic and clinical findings in controls and in patients with diabetes with no, mild and moderate to severe 
neuropathy
Parameter
Controls  
(n=30)
No neuropathy
(n=51)
Mild neuropathy
(n=47)
Moderate 
to severe 
neuropathy 
(n=45)
ANOVA p 
value
Age (years) 54.51±2.3 57.68±1.6 60.16±1.7* 64.1±1.48*† 0.003
Gender (female/male) 15/15 20/31 18/29 16/29 0.4
Ethnicity (European/non- European) 23/7 42/9 31/16 36/9 0.3
Duration of diabetes (years) 0 15±2 18±2 24±3 0.01
HbA1c (mmol/mol) 36.4±0.65 56.21±2.52* 55.99±1.88* 55.37±2.05* <0.0001
BMI (kg/m2) 27.05±0.94 29.09±0.86 28.73±1.0 31.62±1.41* 0.04
Triglycerides (mmol/L) 1.63±0.21 1.41±0.1 1.53±0.14 1.45±0.17 0.7
LDL- C (mmol/L) 2.6±0.14 2.14±0.12* 1.9±0.15* 1.7±0.08*† <0.0001
HDL- C (mmol/L) 1.67±0.1 1.58±0.07 1.47±0.08 1.49±0.1 0.4
All data are expressed as mean±SEM.
*Significant difference compared with controls.
†Significant difference compared with no neuropathy.
ANOVA, analysis of variance; BMI, body mass index; HbA1c, glycated hemoglobin; HDL- C, high- density lipoprotein cholesterol; LDL- C, low- density 
lipoprotein cholesterol.
Table 2 ANCOVA with LSD correction for CCM and other measures of peripheral neuropathy in controls and in patients with 
diabetes with increasing severity of neuropathy
Parameters Control (n=30)
No neuropathy 
(n=51)
Mild neuropathy 
(n=47)
Moderate to severe 
neuropathy (n=45) P value
VPT (V) 7.1±1.80 12.2±1.24* 15.05±1.2* 25.56±1.35*†‡ <0.0001
CPT (°C) 25.38±2.06 21.68±1.44 19.52±1.47* 18.99±1.55* 0.06
WPT (°C) 38.87±0.9 41.65±0.6* 43.47±0.6*† 43.62±0.7*† <0.001
SNCV (m/s) 52.09±2.1 43.14±1.56* 43.5±1.69* 40.19±1.79* <0.001
CNFD (no./mm2) 33.71±1.3 26.61±1.05* 24.47±1.09* 22.4±1.14*† <0.0001
CNBD (no./mm2) 81.52±5.54 64.07±4.39* 58.49±4.76* 45.60±4.5*† <0.0001
CNFL (mm/mm2) 25.07±1.27 23.31±0.96 20.84±1.004* 19.27±1.04*† 0.002
IWL (mm/mm2) 31.69±1.66 24.9±1.26* 22.28±1.31* 19.03±1.36*† <0.0001
ANFL (mm/mm2) 28.38±1.3 24.1±0.98* 21.56±1.02* 19.15±1.06*† <0.0001
Data presented as marginal mean±SEM.
*Significant difference compared with controls.
†Significant difference compared with no neuropathy.
‡Significant difference compared with mild neuropathy.
ANCOVA, analysis of covariance; ANFL, average nerve fiber length; CCM, corneal confocal microscopy; CNBD, corneal nerve branch density; 
CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; CPT, cold perception threshold; IWL, inferior whorl length; LSD, least significant 
difference; SNCV, sural nerve conduction velocity; VPT, vibration perception threshold; WPT, warm perception threshold.
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p<0.0001) and moderate to severe (19.15±1.06, p<0.0001) 
neuropathy compared with controls (28.38±1.3).
Diagnostic utility of different measures of DPN
The ROC curves (table 3) for quantitative sensory testing, 
nerve conduction and CCM for the diagnosis of diabetic 
neuropathy (NDS >3) (figure 2) revealed comparable 
area under the curve (AUC) but variable sensitivities and 
specificities for VPT (AUC 0.79, sensitivity 55%, specificity 
90%), WPT (AUC 0.67, sensitivity 50%, specificity 76%), 
CPT (AUC 0.64, sensitivity 80%, specificity 47%), SNCV 
(AUC 0.70, sensitivity 76%, specificity 54%), CNFD (AUC 
0.71, sensitivity 58%, specificity 83%), CNBD (AUC 0.70, 
sensitivity 69%, specificity 65%), CNFL (AUC 0.68, sensi-
tivity 64%, specificity 67%), IWL (AUC 0.72, sensitivity 
70%, specificity 65%) and ANFL (AUC 0.72, sensitivity 
71%, specificity 66%).
DISCUSSION
Recommendations for the diagnosis of diabetic neurop-
athy require the presence of symptoms and signs and 
abnormal nerve conduction studies or a measure of 
small fiber damage if nerve conduction study (NCS) is 
normal.24 25 Abnormal monofilament testing and VPT 
reflect large nerve fiber damage and predict an increased 
risk of diabetic foot ulceration,26 while thermal sensory 
thresholds and intraepidermal nerve fiber density iden-
tify early small nerve fiber dysfunction27 and degen-
eration,28 respectively. CCM is a rapid, non- invasive 
ophthalmic technique for the quantification of small 
nerve fiber damage in DPN.29 30 Studies have shown a 
relationship between central corneal nerve loss and the 
severity of diabetic neuropathy20 31–34 with good sensi-
tivity and specificity for the diagnosis of DPN.19 33 In a 
small early study using wide- field mapping in patients 
Figure 1 Corneal confocal microscopy images of the central cornea (top row) and the inferior whorl (bottom row) in a healthy 
control (first column) and in patients with no (second column), mild (third column) and moderate to severe (fourth column) 
neuropathy. DPN, diabetic peripheral neuropathy; NDS, Neuropathy Disability Score.
Table 3 Diagnostic performance of quantitative sensory testing, nerve conduction and CCM in the diagnosis of diabetic 
peripheral neuropathy
Neuropathy measure AUC P value Sensitivity (%) Specificity (%) Youden’s cut- off point
VPT 0.79 <0.0001 55 90 17.37
WPT 0.67 <0.001 50 76 44.2
CPT 0.64 <0.002 80 47 27.3
SNCV 0.70 <0.01 76 54 45.9
CNFD 0.71 <0.0001 58 83 23.95
CNBD 0.70 <0.0001 69 65 58.54
CNFL 0.68 <0.0001 64 67 21.6
IWL 0.72 <0.0001 70 65 24.4
ANFL 0.72 <0.0001 71 66 23.4
ANFL, average nerve fiber length; AUC, area under the curve; CCM, corneal confocal microscopy; CNBD, corneal nerve branch density; CNFD, 
corneal nerve fiber density; CNFL, corneal nerve fiber length; CPT, cold perception threshold; IWL, inferior whorl length; SNCV, sural nerve 
conduction velocity; VPT, vibration perception threshold; WPT, warm perception threshold.
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with diabetes with and without neuropathy, we showed 
greater corneal nerve loss at the inferior whorl region.35 
Subsequently, in a cohort of patients with and without 
DPN, we demonstrated that IWL assessment enhanced 
the diagnostic ability of CCM14 30 and it was more mark-
edly reduced in patients with painful diabetic neurop-
athy.16 36 More recently, in a longitudinal study in patients 
with DPN, we have shown more rapid corneal nerve loss 
at the inferior whorl compared with the central cornea.21 
Furthermore, IWL rather than CNFL reduction has been 
associated with increased glucose variability and time 
above range.37
The current study demonstrates progressive loss of 
corneal nerves at the central and inferior whorl region 
with increasing severity of DPN.4 33 Moreover, in patients 
without neuropathy we show that IWL was reduced but 
CNFL was still preserved, consistent with an early distal 
axonopathy in DPN.38 We also show progressive abnor-
mality in the VPT, CPT, WPT and SNCV with increasing 
severity of DPN. In particular we show an early increase 
in the VPT of patients without DPN, which may reflect 
the early involvement of the Pacinian corpuscles.39
For the diagnosis of DPN we show comparable AUCs for 
quantitative sensory testing, nerve conduction and CCM. 
However, the sensitivity and specificity of these tests vary 
and may reflect the limitations of NDS in identifying early 
DPN. Thus VPT had a relatively low sensitivity but high 
specificity, while SNCV and CPT, more precise measures 
of large myelinated fibers, had higher sensitivity but 
lower specificity. However, CNFD had comparable sensi-
tivity and specificity with VPT, while the other measures 
of corneal nerve fiber loss, particularly IWL and ANFL, 
had better sensitivity and specificity in the diagnosis of 
DPN. Perkins et al5 assessed 998 patients with diabetes 
and showed comparable AUC and sensitivity and speci-
ficity in the diagnosis of DPN using the Toronto criteria. 
Pritchard et al13 have reported 90% sensitivity and 50% 
specificity for CNFL compared with 80% sensitivity and 
60% specificity for IWL; however, they used fully auto-
mated software to analyze CCM images, which under-
estimates corneal nerve parameters compared with the 
manual analysis used in this study.
A limitation in the interpretation of our findings is that 
NDS is a relatively crude and subjective measure to diag-
nose and stratify the severity of DPN. Indeed, this may 
explain why the group designated as having no neurop-
athy already have abnormal VPT, CPT, SNCV and corneal 
nerve loss. Nevertheless, this is the largest study to date 
to demonstrate comparable utility of a range of CCM 
measures compared with quantitative sensory testing 
and nerve conduction studies, which are established 
measures of DPN.
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